Rallybio Corp: A Major Strategic Shift and Merger

Rallybio is undergoing a fundamental transformation. On May 31, 2026, the company announced a merger with Avenzo Therapeutics, a private biotech firm. This deal effectively pivots the public company away from its current operations and into a new clinical-stage cancer research business.

1. What is happening?

This deal is a reverse merger. Once it closes, Rallybio will be renamed "Avenzo Therapeutics, Inc." The company will shift its focus entirely to Avenzo’s cancer drug pipeline. Rallybio’s current leadership will step down, and Avenzo’s executive team will take over to run the new entity.

2. The Financial Reality: Dilution

It is important to understand that this deal results in significant dilution for current Rallybio shareholders. Avenzo is using this merger as a vehicle to access public stock markets, supported by $215 million in new funding from a group of investors.

After the merger and the new financing are complete, current Rallybio shareholders will own approximately 2.8% of the combined company. The vast majority of the company will be held by Avenzo’s original owners and the new investors.

3. The "Bonus" for Shareholders: CVRs

Current Rallybio shareholders will receive Contingent Value Rights (CVRs). These are essentially contracts that could pay out if Rallybio’s "Legacy Assets"—such as existing research programs and potential payments from past deals like the agreement with Recursion Pharmaceuticals—generate money in the future.

• The Catch: The value of these rights depends entirely on the company successfully selling or licensing these old programs. There is no guarantee that these deals will happen or generate any cash. Furthermore, these rights cannot be traded or transferred, and they do not grant you any ownership stake in the new Avenzo Therapeutics.

4. What this means for your investment

• A Complete Pivot: Your investment is moving from rare blood disorders and maternal health to a focus on cancer drug development.
• Leadership Change: The board of directors and management team are being replaced to align with Avenzo’s strategy.
• Lock-up Periods: To help stabilize the stock price, Avenzo’s insiders are prohibited from selling their shares for 180 days after the merger closes.
• High Volatility: The transition period is inherently uncertain. The market’s reaction to a new cancer-focused strategy can be unpredictable, and the timing of the deal's closing is subject to various conditions.

5. Next Steps for the Deal

• Shareholder Vote: Rallybio stockholders must vote to approve the merger, the name change, and a reverse stock split. The reverse split is intended to consolidate shares and ensure the company maintains its listing on the stock exchange.
• Regulatory Approval: The deal must pass standard regulatory reviews and meet specific financial requirements before it can officially close.

How to approach this decision

When deciding how to handle your position, ask yourself if you are interested in the long-term potential of Avenzo’s cancer pipeline or if you were primarily invested in Rallybio’s original mission.

Because your ownership percentage will be significantly reduced, the value of your current holding is now tied to the success of a completely different business model. If you choose to stay, you are essentially betting on the success of the new Avenzo management team and their clinical-stage cancer drugs. If you are uncomfortable with this shift or the dilution, you may want to re-evaluate your position before the merger vote takes place.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and does not constitute financial advice. Always do your own research and consult with a professional before making investment decisions.